Concert Pharmaceuticals’ alopecia drug reduced disease severity in nearly half of the patients who received a higher dose.
The series C sets Harpoon up to move candidates targeting mesothelin and BCMA into human testing next year.
EVERSANA delivers a fully-integrated service portfolio to help life science leaders create value for key constituents across the product lifecycle.
Boehringer Ingelheim Venture Fund co-led the financing to tee Amal up to take lead colorectal cancer vaccine ATP128 into the clinic next year.
Two months after rumblings emerged that Moderna Therapeutics was prepping what would be biotech’s biggest IPO, the company has come through.
After posting sinking response rates, Nektar unveiled new results for its NKTR-214 and Opdivo melanoma therapy that showed rates holding just steady.
Aduro has reported first data for STING agonist ADU-S100, hoping to rebuild confidence in the mechanism after lackluster data from Merck at ESMO.
Gilead unveiled phase 2 data showing its FXR agonist improved liver biochemistry and cholestasis in patients with primary sclerosing cholangitis.
Jnana’s Joanne Kotz to be CEO; BioCardia brings on new clinical VP for phase 3; and Biomatics recruits biopharma veterans for $300M healthcare fund.
The gift will enable Harvard to set up an incubator for biotech startups and invest in its research capabilities.
Seal Rock Therapeutics is officially launching with plans to bring its lead asset, an ASK1 inhibitor for NASH, into human trials in 2020.
